Tyra Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TYRA research report →
Range $29 – $56
Price Chart
About the company
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer.
- CEO
- Todd Harris
- IPO
- 2021
- Employees
- 87
- HQ
- Carlsbad, CA, US
Get TickerSpark's AI analysis on TYRA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.39B
- P/E
- -7.62
- PEG
- 0.24
- P/S
- 0.00
- P/B
- 2.01
- EV/EBITDA
- -5.41
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -40.12%
- ROIC
- -26.12%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-132,762,000
- Net Income
- $-119,947,000-38.7%
- EPS
- $-2.01-33.1%
- OCF Growth
- -36.4%
- FCF Growth
- -35.3%
- 52W High
- $40.65
- 52W Low
- $18.25
- 50D MA
- $21.30
- 200D MA
- $29.18
- Beta
- 0.75
- RSI (14)
- 45
- Avg Volume
- 852.97K
No earnings-call transcripts are available for TYRA yet.
- Free Float
- 76.7%
- Shares Outstanding
- 68.98M
- Float Shares
- 52.91M
of shares held by institutions
177 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 12.20M | 0 |
| Fmr LLC | 10.54M | ▲ 1.62M |
| Jupiter Topco LLC | 4.35M | ▲ 4.35M |
| Janus Henderson Group Ltd. | 3.89M | ▲ 955.15K |
| Alta Partners Management Company, L.P. | 3.82M | 0 |
| Nextech Invest Ltd. | 3.55M | ▼ 502.28K |
| Siren, L.L.C. | 3.40M | ▲ 2.67M |
| Blackrock, Inc. | 3.36M | ▲ 327.39K |
| Tcg Crossover Management, LLC | 3.25M | 0 |
| Price T Rowe Associates Inc | 2.78M | ▲ 1.80M |
| State Street Corp | 2.00M | ▼ 142.92K |
| Commodore Capital LP | 1.88M | ▼ 600.00K |
Held by 249 ETFs
Biggest fund positions in TYRA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 15, 26 | Harris Todd | other | 864 |
| Sep 15, 26 | Rueb Yuliya | other | 2,925 |
| Sep 15, 26 | Fuhrman Alan | other | 951 |
| Sep 15, 26 | RA CAPITAL MANAGEMENT, L.P. | buy | 9,078,529 |
| Sep 9, 26 | Verjee Rehan | buy | 971.894 |
| May 28, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 13,160 |
| May 28, 26 | Verjee Rehan | other | 13,160 |
| May 28, 26 | Moran Susan | other | 13,160 |
| May 28, 26 | Simson Jake | other | 13,160 |
| May 28, 26 | Gulfo Adele M. | other | 13,160 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TYRA coverage
Recent articles, reports, and earnings notes.
No research on TYRA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TYRA report →Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights
prnewswire.com · Nov 10
Tyra Biosciences to Participate in Upcoming Investor Conferences
prnewswire.com · Nov 5
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
prnewswire.com · Oct 15
Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weeks
zacks.com · Oct 14
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
globenewswire.com · Oct 13
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
prnewswire.com · Oct 8
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
globenewswire.com · Oct 6
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
prnewswire.com · Oct 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.